|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Oral (tablet form)|
|Biological half-life||2.5-3.5 hours|
|Excretion||Renal (25-30% unchanged [Oral])|
|CAS Registry Number|
|Molecular mass||337.449 g/mol|
|(what is this?)|
Famotidine (//l trade name Pepcid) is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Unlike cimetidine, the first H2 antagonist, famotidine has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other drugs.
- Relief of heartburn, acid indigestion, and sour stomach
- Treatment for gastric and duodenal ulcers
- Treatment for pathologic gastrointestinal hypersecretory conditions such as Zollinger-Ellison syndrome and multiple endocrine adenomas
- Treatment for Gastroesophageal reflux (GERD)
- Treatment for Esophagitis
- Part of a multidrug regimen for H. pylori eradication, although omeprazole may be somewhat more effective.
- Prevention of NSAID induced peptic ulcers.
- Given to surgery patients before operations to reduce the risk of aspiration pneumonitis.
Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States and Canada, 10 mg and 20 mg tablets, sometimes in combination with an antacid, are available OTC. Larger doses still require a medical prescription.
Famotidine was developed by Yamanouchi Pharmaceutical Co. It was licensed in the mid-80s by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 9 times more potent than ranitidine, and 32 times more potent than cimetidine.
In the United States and Canada, a product called Pepcid Complete, which combines famotidine with an antacid in a chewable tablet to quickly relieve the symptoms of excess stomach acid, is available. In the UK, this product was known as Pepcidtwo prior to its discontinuation in April 2015.
Famotidine suffers from poor bioavailability (50%), as it is poorly soluble in the low pH of the stomach. When used in combination with antacids, it promotes local delivery of these drugs to the receptor of the parietal cell wall. Therefore, researchers are developing innovative formulations of tablets, such as gastroretentive drug delivery systems. Such tablets are retained in the stomach for a longer period of time, thereby improving the bioavailability of drugs. Local delivery also increases bioavailability at the stomach wall receptor site and increases the efficacy of drugs to reduce acid secretion.
- Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.
- Humphries TJ, Merritt GJ (August 1999). "Review article: drug interactions with agents used to treat acid-related diseases" (pdf). Aliment. Pharmacol. Ther. 13 (Suppl 3): 18–26. doi:10.1046/j.1365-2036.1999.00021.x. PMID 10491725.
- Kanayama, S (January 1999). "[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].". Nihon rinsho. Japanese journal of clinical medicine 57 (1): 153–6. PMID 10036954.
- Soga, T; Matsuura, M; Kodama, Y; Fujita, T; Sekimoto, I; Nishimura, K; Yoshida, S; Kutsumi, H; Fujimoto, S (August 1999). "Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?". Journal of gastroenterology 34 (4): 435–40. PMID 10452673.
- Borody, TJ; Andrews, P; Fracchia, G; Brandl, S; Shortis, NP; Bae, H (October 1995). "Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.". Gut 37 (4): 477–81. PMID 7489931.
- Hu, FL; Jia, JC; Li, YL; Yang, GB (2003). "Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.". The Journal of international medical research 31 (6): 469–74. PMID 14708410.
- Kirika, NV; Bodrug, NI; Butorov, IV; Butorov, SI (2004). "[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].". Terapevticheskii arkhiv 76 (2): 18–22. PMID 15106408.
- Fujiwara, Y; Higuchi, K; Nebiki, H; Chono, S; Uno, H; Kitada, K; Satoh, H; Nakagawa, K; Kobayashi, K; Tominaga, K; Watanabe, T; Oshitani, N; Arakawa, T (June 2005). "Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.". Alimentary pharmacology & therapeutics. 21 Suppl 2: 10–8. PMID 15943841.
- La Corte, R; Caselli, M; Castellino, G; Bajocchi, G; Trotta, F (June 1999). "Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.". Drug safety 20 (6): 527–43. PMID 10392669.
- Laine, L; Kivitz, AJ; Bello, AE; Grahn, AY; Schiff, MH; Taha, AS (March 2012). "Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.". The American journal of gastroenterology 107 (3): 379–86. doi:10.1038/ajg.2011.443. PMID 22186979.
- Escolano, F; Castaño, J; López, R; Bisbe, E; Alcón, A (October 1992). "Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery.". British journal of anaesthesia 69 (4): 404–6. PMID 1419452.
- Vila, P; Vallès, J; Canet, J; Melero, A; Vidal, F (November 1991). "Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine.". Anaesthesia 46 (11): 967–9. PMID 1750602.
- Jahr, JS; Burckart, G; Smith, SS; Shapiro, J; Cook, DR (July 1991). "Effects of famotidine on gastric pH and residual volume in pediatric surgery.". Acta anaesthesiologica Scandinavica 35 (5): 457–60. PMID 1887750.
- http://www.petmd.com/pet-medication/famotidine. Missing or empty
- Fogg TB, Semple D (29 November 2007). "Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions". BestBets. Manchester, England: Manchester Royal Infirmary. Retrieved 26 April 2011.
- Pepcid Complete
- http://www.nlm.nih.gov/medlineplus/druginfo/meds/a687011.html. Missing or empty
- "Pepcid Side Effects & Drug Interactions". RxList.com. 2008. Retrieved 2008-07-31.
- US patent 4283408, HIRATA YASUFUMI; YANAGISAWA ISAO; ISHII YOSHIO; TSUKAMOTO SHINICHI; ITO NORIKI; ISOMURA YASUO; TAKEDA MASAAKI, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 1981-08-11
- "Sankyo Pharma". Skyscape Mediwire. 2002. Retrieved 2009-10-30.[dead link]
- Howard, JM; Chremos, AN; Collen, MJ; McArthur, KE; Cherner, JA; Maton, PN; Ciarleglio, CA; Cornelius, MJ; Gardner, JD; Jensen, RT (April 1985). "Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.". Gastroenterology 88 (4): 1026–33. PMID 2857672.
- http://www.medicines.org.uk/emc/medicine/20012. Retrieved 7 June 2015. Missing or empty
- "Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine". Farmavita.Net. 2008. Retrieved 2009-01-30.
- Meskanen, K; Ekelund, H; Laitinen, J; Neuvonen, PJ; Haukka, J; Panula, P; Ekelund, J (August 2013). "A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.". Journal of Clinical Psychopharmacology 33 (4): 472–478. doi:10.1097/JCP.0b013e3182970490. PMID 23764683.